Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 165.72 8.3 (5.27%) Market Cap: 20.96 Bil Enterprise Value: 19.89 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 67/100

Alnylam Pharmaceuticals Inc at Morgan Stanley Healthcare Conference Transcript

Sep 09, 2019 / 02:30PM GMT
Release Date Price: $82.69 (+3.60%)
David Neil Lebowitz
Morgan Stanley, Research Division - VP

Good morning. Before I get going, let me just read our disclosures. Please note that all-important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, are up here at the Morgan Stanley public website at www.morganstanley.com/researchdisclosures or at the registration desk.

Once again, thank you for attending. I'm David Lebowitz, one of the biotechnology analysts here. And on stage with me, I have from Alnylam Pharmaceuticals, CEO, John Maraganore; and the Head of Business Development or Head of Business, Andy Orth. Thank you so much for being here. I guess, just quickly, give a little bit top level on Alnylam and your mission.

John M. Maraganore
Alnylam Pharmaceuticals, Inc. - CEO & Executive Director

Sure. Thanks, Dave. Pleasure to be here. Alnylam is now a global commercial company that is developing, commercializing RNAi therapeutics around the world. Our advanced

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot